Search results for "PHASE"

showing 10 items of 6344 documents

Novel therapeutic targets to improve IVF outcomes in endometriosis patients: a review and future prospects

2020

AbstractBACKGROUNDPatients with endometriosis often experience infertility and have poor IVF outcomes, with low fertilization and pregnancy rates. Although many theories have tried to explain the mechanisms underlying infertility in these patients, none of them is conclusive.OBJECTIVE AND RATIONALEIn this review, we discuss the pathologic mechanisms through which endometriosis likely leads to infertility along with the therapeutic options used to date to treat endometriosis-related infertility and, thereby, to improve IVF outcomes in patients with endometriosis.SEARCH METHODSWe performed a comprehensive literature search of clinical outcomes in endometriosis and the molecular mechanisms con…

0301 basic medicineInfertilityPregnancy Ratemedia_common.quotation_subjectEndometriosisEndometriosisContext (language use)FertilityFertilization in VitroDiseaseBioinformatics03 medical and health sciences0302 clinical medicinePregnancyFollicular phasemedicineHumansEmbryo ImplantationAromatasemedia_common030219 obstetrics & reproductive medicinebiologybusiness.industryObstetrics and Gynecologymedicine.disease030104 developmental biologyReproductive Medicinebiology.proteinFemalebusinessInfertility FemaleEmbryo qualityHuman Reproduction Update
researchProduct

Synthesis and in vitro leishmanicidal activity of novel [1,2,3]triazolo[1,5-a]pyridine salts

2017

Leishmaniasis remains a significant worldwide problem; it is of great interest to develop new drugs to fight this disease. Recently we described some [1,2,3] triazolo[1,5-a] pyridine compounds with significant leishmanicidal activity. The importance of water solubility in drug action made us realise that we could transform non charged triazolopyridines into charged analogues that could increase the degree of water solubility. With this objective we report here the synthesis of novel [1,2,3] triazolo[1,5-a] pyridinium salts 2-7 from triazolopyridines 1, and the study of their in vitro leishmanicidal activity. The activity was tested on Leishmania infantum, Leishmania braziliensis and Leishma…

0301 basic medicineInhibitorGeneral Chemical EngineeringLeishmania donovaniDrug action01 natural sciences03 medical and health scienceschemistry.chemical_compoundparasitic diseasesTriazolopyridinesAmastigoteCytotoxicityImidazolebiologyChronic phases010405 organic chemistryChemistryBinding.Vivo trypanosomicidal activityGeneral Chemistrybiology.organism_classificationLeishmania braziliensisIn vitro0104 chemical sciencesChemistry030104 developmental biologyBiochemistry123-triazolesAntibacterial activityPyridiniumLeishmania infantumDerivativesRSC Advances
researchProduct

Cyclin-Dependent Kinase 4 Regulates Adult Neural Stem Cell Proliferation and Differentiation in Response to Insulin

2017

Abstract Insulin is one of the standard components used to culture primary neurospheres. Although it stimulates growth of different types of cells, the effects of insulin on adult neural stem cells (NSCs) have not been well characterized. Here, we reveal that insulin stimulates proliferation, but not survival or self-renewal, of adult NSCs. This effect is mediated by insulin receptor substrate 2 (IRS2) and subsequent activation of the protein kinase B (or Akt), leading to increased activity of the G1-phase cyclin-dependent kinase 4 (Cdk4) and cell cycle progression. Neurospheres isolated from Irs2-deficient mice are reduced in size and fail to expand in culture and this impaired proliferati…

0301 basic medicineInsulin Receptor Substrate ProteinsNeurogenesisCellular differentiationBiologyAdult neurogenesisMice03 medical and health sciencesNeural Stem CellsCyclin-dependent kinaseNeurosphereAnimalsInsulinPhosphorylationNeuritogenesisProtein kinase BCell ProliferationCell CycleG1 PhaseCyclin-dependent kinaseCyclin-Dependent Kinase 4Cell DifferentiationCell BiologyIRS2Neural stem cellCell biology030104 developmental biologyVentricular-subventricular zoneInsulin Receptor Substrate Proteinsbiology.proteinMolecular MedicineNeurospheresbiological phenomena cell phenomena and immunityStem cellDevelopmental BiologyStem Cells
researchProduct

The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model.

2021

Abstract STUDY QUESTION Does LH protect mouse oocytes and female fertility from alkylating chemotherapy? SUMMARY ANSWER LH treatment before and during chemotherapy prevents detrimental effects on follicles and reproductive lifespan. WHAT IS KNOWN ALREADY Chemotherapies can damage the ovary, resulting in premature ovarian failure and reduced fertility in cancer survivors. LH was recently suggested to protect prepubertal mouse follicles from chemotoxic effects of cisplatin treatment. STUDY DESIGN, SIZE, DURATION This experimental study investigated LH effects on primordial follicles exposed to chemotherapy. Seven-week-old CD-1 female mice were randomly allocated to four experimental groups: C…

0301 basic medicineLHAlkylating Agentsfertility preservationmedia_common.quotation_subjectDNA repair LH cancer chemotherapy fertility preservation follicle protection ovoprotectionDNA repairOvaryMice SCIDBiologychemotherapyAndrology03 medical and health sciencesMice0302 clinical medicineOvarian FollicleMice Inbred NODPregnancyFollicular phasemedicineAnimalsHumanscancerFertility preservationOvarian follicleOvarian reserveOvarian ReserveOvulationmedia_commonReproductive Biology030219 obstetrics & reproductive medicineRehabilitationObstetrics and GynecologyOriginal ArticlesOocytemedicine.diseaseAcademicSubjects/MED00905Premature ovarian failure030104 developmental biologymedicine.anatomical_structureReproductive Medicinefollicle protectionovoprotectionlipids (amino acids peptides and proteins)FemaleHuman reproduction (Oxford, England)
researchProduct

The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

2016

Abstract: Introduction: Molecular alterations in neurotrophic tyrosine kinase (NTRK) genes have been identified in several solid tumors including lung cancer. Pre-clinical and clinical evidence suggested their potential role as oncogenic drivers and predictive biomarkers for targeted inhibition, leading to the clinical development of a new class of compounds blocking the NTRK molecular pathway, which are currently undner early clinical investigation. Area covered: This review describes the biology of the NTRK pathway and its molecular alterations in lung cancer. It focuses on the pre-clinical and clinical development of emerging NTRK inhibitors, which have shown very promising activity in e…

0301 basic medicineLung NeoplasmsNTRKinhibitorsNTRK1/2/3Settore MED/06 - Oncologia Medicamedicine.medical_treatmentReceptor Protein-Tyrosine KinasesEntrectinibPharmacologyTargeted therapy03 medical and health sciences0302 clinical medicineMedicineAnimalsHumansPharmacology (medical)In patientNTRKinhibitorLung cancerProtein Kinase InhibitorsTrkA/B/CPharmacologyNTRK1/2/3; TrkA/B/C; NTRKinhibitors; targeted therapy; lung cancerbiologybusiness.industryPharmacology. TherapyReceptor Protein-Tyrosine KinasesGeneral Medicinemedicine.diseasetargeted therapySettore CHIM/08 - Chimica Farmaceuticalung cancer030104 developmental biology030220 oncology & carcinogenesisbiology.proteinCancer researchbusinessEarly phaseTyrosine kinaseNeurotrophin
researchProduct

Unusual roles of caspase-8 in triple-negative breast cancer cell line MDA-MB-231

2015

Triple-negative breast cancer (TNBC) is a clinically aggressive form of breast cancer that is unresponsive to endocrine agents or trastuzumab. TNBC accounts for ~10-20% of all breast cancer cases and represents the form with the poorest prognosis. Patients with TNBC are at higher risk of early recurrence, mainly in the lungs, brain and soft tissue, therefore, there is an urgent need for new therapies. The present study was carried out in MDA-MB-231 cells, where we assessed the role of caspase-8 (casp-8), a critical effector of death receptors, also involved in non‑apoptotic functions. Analysis of casp-8 mRNA and protein levels indicated that they were up-regulated with respect to the normal…

0301 basic medicineMDA-MB-231 cellCancer ResearchDown-RegulationTriple Negative Breast NeoplasmsTransfectionResting Phase Cell Cycle03 medical and health sciencesKruppel-Like Factor 40302 clinical medicineHMGA2Breast cancerCell Line TumormedicineHumansRNA Small InterferingCaspase-8 unusual roleTriple-negative breast cancerCaspase 8Triple-negative breast cancer cellbiologyOncogeneCaspase-8 knockdownCell CycleG1 PhaseCancerCell cyclemedicine.diseaseMolecular medicineKLF4Invasivity and metastasi030104 developmental biologyOncologyKLF4030220 oncology & carcinogenesisbiology.proteinCancer researchFemaleCell cycle regulator
researchProduct

An Attachment-Independent Biochemical Timer of the Spindle Assembly Checkpoint.

2017

The spindle assembly checkpoint (SAC) generates a diffusible protein complex that prevents anaphase until all chromosomes are properly attached to spindle microtubules. A key step in SAC initiation is the recruitment of MAD1 to kinetochores, which is generally thought to be governed by the microtubule-kinetochore (MT-KT) attachment status. However, we demonstrate that the recruitment of MAD1 via BUB1, a conserved kinetochore receptor, is not affected by MT-KT interactions in human cells. Instead, BUB1:MAD1 interaction depends on BUB1 phosphorylation, which is controlled by a biochemical timer that integrates counteracting kinase and phosphatase effects on BUB1 into a pulse-generating incohe…

0301 basic medicineMad1KinetochoreBUB1Nuclear ProteinsCell Cycle ProteinsCell BiologySpindle ApparatusBiologyProtein Serine-Threonine KinasesCell biologySpindle apparatus03 medical and health sciencesSpindle checkpoint030104 developmental biology0302 clinical medicineHEK293 CellsHumansTimerKinetochoresMolecular BiologyMitosis030217 neurology & neurosurgeryAnaphaseHeLa CellsMolecular cell
researchProduct

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.

2015

Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve prolonged disease-free survival. Blinatumomab, a bispecific T-cell engaging antibody construct, transiently links CD3-positive T cells to CD19-positive B cells. This phase 2 study evaluated stepwise (9-28-112 μg/d with weekly dose increases; n = 23) or flat (112 μg/d; n = 2) dosing of blinatumomab by continuous infusion, with dexamethasone prophylaxis, in patients with relapsed/refractory DLBCL. Patients received a median of 3 prior lines of therapy. Median time since last regimen was 1.5 months. Seventeen patients ended treatment in cycle 1 (induction), 7 in cycle 2 (consolidation), and 1 in retreatment. Am…

0301 basic medicineMaleCD3 ComplexClinical Trials and ObservationsSalvage therapyPhases of clinical researchKaplan-Meier EstimateBiochemistryGastroenterologyDexamethasone0302 clinical medicineRecurrenceAntibodies BispecificMedicineMolecular Targeted TherapyFatigueRemission InductionHematologyMiddle AgedTumor Burden030220 oncology & carcinogenesisBlinatumomabFemaleImmunotherapyLymphoma Large B-Cell Diffusemedicine.drugAdultmedicine.medical_specialtyFeverImmunologyAntigens CD19Antineoplastic AgentsDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesAntigens NeoplasmInternal medicineHumansDosingAdverse effectAgedSalvage TherapyDose-Response Relationship Drugbusiness.industryCell Biologymedicine.diseaseLymphomaSurgeryRegimen030104 developmental biologyNervous System DiseasesbusinessDiffuse large B-cell lymphomaBlood
researchProduct

Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.

2019

The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. ispartof: EUROPEAN JOURNAL OF CANCER vol:124 pages:67-…

0301 basic medicineMaleCancer ResearchEsophageal NeoplasmsADJUVANT CHEMOTHERAPY0302 clinical medicineEUROPEAN ORGANIZATIONMultidisciplinary approachGastricPerioperativeStage (cooking)AdjuvantClinical OncologyMISMATCH REPAIR DEFICIENCYdigestive oral and skin physiologyGastro oesophageal junctionOPEN-LABELPrognosisJCOGhumanitiesEORTCOncology030220 oncology & carcinogenesisCLINICAL-RESEARCHFemaleImmunotherapyEsophagogastric JunctionRANDOMIZED PHASE-IILife Sciences & Biomedicinemedicine.medical_specialtyStage ii03 medical and health sciencesStomach NeoplasmsmedicineChemotherapyHumansNeoplasm StagingScience & Technologybusiness.industryPERIOPERATIVE CHEMOTHERAPYGeneral surgeryCancerADENOCARCINOMAPLUS OXALIPLATINmedicine.diseaseSurvival Analysisdigestive system diseases030104 developmental biologyNeoplasm stagingbusinessTRIAL DESIGNEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

2016

Background:This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC).Methods:Patients received 800-mg intravenous necitumumab (day 1; 2-week cycles), followed by oxaliplatin 85 mg m -2, folinic acid 400 mg m -2, and 5-fluorouracil (400 mg m -2 bolus then 2400 mg m -2 over 46 h). Radiographic evaluation was performed every 8 weeks until progression. Primary endpoint was objective response rate.Results:Forty-four patients were enrolled and treated. Objective response rate was 63.6% (95% confidence interval 47.8-77.6); complete response was observed in …

0301 basic medicineMaleCancer ResearchOrganoplatinum CompoundsLeucovorinPhases of clinical researchmedicine.disease_causeGastroenterology0302 clinical medicineadvanced colorectal cancerAntineoplastic Combined Chemotherapy ProtocolsClinical endpointNeoplasm MetastasisNecitumumabModified FOLFOX6Aged 80 and overnecitumumabAntibodies MonoclonalMiddle AgedOxaliplatinTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisFemaleKRASFluorouracilColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyEGFRNeutropeniamodified FOLFOX6Antibodies Monoclonal HumanizedDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciencesFolinic acidInternal medicinemedicineKRASHumansAdvanced colorectal cancerAgedbusiness.industrymedicine.diseaseSurvival AnalysisSurgeryOxaliplatinCancérologie030104 developmental biologyClinical StudybusinessNecitumumabBritish Journal of Cancer
researchProduct